梯瓦製藥 TEVA 深滬

已收盤 08-07 16:00:00 美东时间

35.36

+0.550

+1.58%

華盛通

立即下載

最高35.77
今開35.00
成交量 427.19万股
最低 34.87
昨收 34.81
總市值 4119.44万
52周最高 37.345
市盈率 ^靜 28.94
換手率 366.69%
52周最低 17.33
委比 0.00%
總股本 0.01亿
歷史最高 69.8535
量比 0.86
振幅 2.59%
歷史最低 6.07
每手 1
風險率 6.16%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

SA Asks: What's the outlook for Big Pharma M&A?

Big Pharma moved back into the spotlight last week following a Financial Times report that Bristol Myers Squibb (BMY) was in merger talks with AstraZeneca (AZN), a development that was later denied by...

08-09 03:28
NRx Pharmaceuticals To Host Conference Call And Q&A Session On August 10 To Discuss FDA's Completion Of First-Cycle Review Of Its ANDA For Preservative-Free Ketamine

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and Q&A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA's completion of first-cycle review o...

08-08 04:03
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

NRx Pharmaceuticals will host a conference call on August 10, 2026, at 8:30 a.m. ET to discuss the FDA's review of its ANDA for preservative-free ketamine. Participants include Jonathan Javitt, MD, MPH, CEO; Glenn Tyson, CCO; and Chaim Hurvitz, a former Teva executive. The call will cover regulatory and commercial plans. A live webcast will be available on the company’s website, with a replay afterward. NRx is developing therapeutics for CNS diso...

08-07 20:01
财报速睇 | 梯瓦制药 2026财年Q2营收41.42亿美元，同比下降0.8%；归母净利润亏损5.76亿美元，由盈转亏

华盛资讯7月30日讯，梯瓦制药公布2026财年Q2业绩，公司Q2营收41.42亿美元，同比下降0.8%，归母净利润亏损5.76亿美元，由盈转亏。

07-30 08:10
财报速睇 | 梯瓦制药 2026财年Q2营收41.42亿美元，同比下降0.8%；归母净利润亏损5.76亿美元，由盈转亏

华盛资讯7月29日讯，梯瓦制药公布2026财年Q2业绩，公司Q2营收41.42亿美元，同比下降0.8%，归母净利润亏损5.76亿美元，由盈转亏。

07-29 19:38
财报速睇 | 梯瓦制药 2026财年Q2营收41.42亿美元，同比下降0.8%；归母净利润亏损5.76亿美元，由盈转亏

华盛资讯7月29日讯，梯瓦制药公布2026财年Q2业绩，公司Q2营收41.42亿美元，同比下降0.8%，归母净利润亏损5.76亿美元，由盈转亏。

07-29 19:34
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级

今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元

07-29 11:37
Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $44.

07-28 23:00
特朗普拟对进口仿制药征关税：将如何影响药价、药企与药品供应链

　　核心要点特朗普计划设立两年缓冲期，之后对进口仿制药最高征收 200% 关税，以此推动药品在美国本土生产。　　仿制药企业利润率微薄，相比原研药企更难消化关...

07-23 00:25
美股盘前 | 沃达丰涨2.94%，Woodside Energy Group Ltd Sponsored ADR涨2.38%

沃达丰涨2.94%；Woodside Energy Group Ltd Sponsored ADR涨2.38%；梯瓦制药涨2.05%

07-17 16:10

派息除權日	每股總股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-21	0.04	1991-09-19
1991-05-20	0.04	1991-07-20
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-17	0.04	1990-09-17
1989-05-22	0.04	1989-06-19
1988-12-06	0.04	1988-12-30
1988-09-08	0.04	1988-10-05
1988-06-10	0.03	1988-07-20
1988-04-11	0.03	1988-05-16
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-09	0.04	1987-08-05
1987-06-22	0.03	1987-07-14
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名稱	梯瓦制药
行業分類	制药
業務描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦製藥 TEVA 深 滬

35.36

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

梯瓦製藥 TEVA 深滬